LQDA logo

Liquidia Corporation Stock Price

NasdaqCM:LQDA Community·US$2.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 20 Fair Values set on narratives written by author

LQDA Share Price Performance

US$24.44
13.35 (120.38%)
US$24.44
13.35 (120.38%)
Price US$24.44

LQDA Community Narratives

There are no narratives available yet.

Snowflake Analysis

High growth potential with mediocre balance sheet.

1 Risk
2 Rewards

Liquidia Corporation Key Details

US$19.3m

Revenue

US$5.9m

Cost of Revenue

US$13.4m

Gross Profit

US$165.0m

Other Expenses

-US$151.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-1.76
69.29%
-784.54%
1,274.7%
View Full Analysis

About LQDA

Founded
2004
Employees
170
CEO
Roger Jeffs
WebsiteView website
www.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Recent LQDA News & Updates

Recent updates

No updates